Sucampo Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating

Leslie Hanson
December 7, 2017

The move comes after 5 months positive chart setup for the $698.47 million company. It was reported on Dec, 4 by Barchart.com. (NASDAQ:SCMP), we have noted that performance for the previous week is 24.02%. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Brands had 88 analyst reports since July 1, 2015 according to SRatingsIntel. SCMP's financial leverage ratio is 8.79, which indicates that the company's asset base is primarily funded by debt. The company was downgraded on Tuesday, January 12 by Dundee Securities. RBC Capital Markets maintained the stock with "Outperform" rating in Wednesday, January 25 report. Brands, Inc. (NYSE:YUM) has "Top Pick" rating given on Wednesday, October 21 by RBC Capital Markets. Sucampo Pharmaceuticals has an average rating of Buy and an average target price of $16.00. (NASDAQ:SCMP). Dekabank Deutsche Girozentrale invested in 0% or 11,100 shares. Therefore 73% are positive. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $17.24. The stock now has a consensus rating of "Buy" and an average price target of $16.00. The firm has "Hold" rating given on Thursday, August 6 by WallachBeth Capital.

The Return on Invested Capital (aka ROIC) for Sucampo Pharmaceuticals, Inc. A stock experiencing a high level of volatility has a higher ATR, and a low volatility stock has a lower ATR. Return on equity was booked as -148.20% while return on assets was -33.50%. (NASDAQ:SCMP) on Tuesday, February 9 with "Buy" rating. (NASDAQ:SCMP), with 4 analysts believing it is a strong buy. Vanguard Group Inc. increased its holdings in Sucampo Pharmaceuticals by 48.9% in the 1st quarter. WallachBeth Capital has "Hold" rating and $27 target. Brands, Inc. (NYSE:YUM) earned "Buy" rating by Credit Suisse on Friday, May 26. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Tuesday, October 3rd. If RVOL is less than 1 it is not In Play on this trading day and Investors may decide not to trade it. Its down 0.06, from 1.39 in 2017Q1.

Watching some historical volatility numbers on shares of Sucampo Pharmaceuticals, Inc. 86 funds opened positions while 181 raised stakes. Investors may be watching shares for trading volume that is out of the ordinary. Great West Life Assurance Can owns 35,778 shares. This presents short term, intermediate and long term technical levels of Tetraphase Pharmaceuticals, Inc. (NASDAQ:SCMP). The circumstantial evidence specially high/lower types of ownership has a vital gauge for investing research process and it should be done carefully, as rather than offering help in finding value; it can sometimes give false signals and lead an investor astray. Stifel Financial Corp owns 12,225 shares or 0% of their USA portfolio. After this purchase, 30,228 common shares of SCMP are directly owned by the insider, with total stake valued at $429,238.


Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) scores higher than Synergy Pharmaceuticals Inc. (NASDAQ:ODP) higher to the next line of resistance at $3.56 a share. Alps Advisors Inc holds 0% or 41,940 shares. Jpmorgan Chase And holds 2.08M shares or 0.04% of its portfolio. Louisiana State Employees Retirement Sys has invested 0.07% in Yum!

Taking a broader look brokerage firms' analysts on the street with an expectant view have Sucampo Pharma Inc (NASDAQ:SCMP) high price target of $23 and with a conservative view have low price target of $7. "(SCMP) PT at $16.00" was first reported by Week Herald and is the sole property of of Week Herald. The stock's price to sales ratio for trailing twelve months is 2.39 and price to book ratio for the most recent quarter is 15.64, whereas price to cash per share for the most recent quarter are 7.97. (NasdaqGM:SCMP) stands at 0.095407.

Previously Sucampo Pharma Inc (NASDAQ:SCMP) reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. Active Investors have to observe some key indicators about shares of Tetraphase Pharmaceuticals, Inc. The stock has a market cap of $598.12, a P/E ratio of 8.77, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The companyÂ's marketed product includes AMITIZA, a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC) in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER